

# Treatment Patterns Among Patients With Atopic Dermatitis (AD) Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database

Lawrence F. Eichenfield,<sup>1</sup> Marco DiBonaventura,<sup>2</sup> Jason Xenakis,<sup>2</sup> Marie-Helene Lafeuille,<sup>3</sup> Mei Sheng Duh,<sup>4</sup> Jennifer W. Wu,<sup>3</sup> Mark Levenberg,<sup>5</sup> Joseph C. Cappelleri,<sup>6</sup> Vanja Sikirica<sup>5</sup>

<sup>1</sup>UC San Diego and Rady Children's Hospital-San Diego, San Diego, CA, USA; <sup>2</sup>Pfizer Inc., New York, NY, USA; <sup>3</sup>Analysis Group, Montreal, QC, Canada; <sup>4</sup>Analysis Group, Boston, MA, USA; <sup>5</sup>Pfizer Inc., Collegeville, PA, USA; <sup>6</sup>Pfizer Inc., Groton, CT, USA

**Presented at the American Academy of Dermatology 2020 Annual Meeting;  
March 20-24, 2020; Denver, Colorado**



# Disclosures

**LFE** has served as a scientific adviser, consultant, and/or clinical study investigator for Pfizer Inc., AbbVie, Almirall, Amgen, Asana Biosciences, Cutanea, Dermavant, Dermira, Dr. Reddy's Laboratory, DS Biopharma, Eli Lilly, Forté Pharma, Galderma, Glenmark, Incyte, LEO Pharma, Matrisys Bioscience, Novan, Novartis, Ortho Dermatologics/Valeant, Sanofi-Regeneron, Sanofi Genzyme, TopMD, UCB, and Verrica.

**MD, JX, ML, JCC, VS** are employees and stockholders of Pfizer Inc.

**MHL, MSD** are employees of Analysis Group, which received research funding from Pfizer Inc., to conduct this study.

**JWW** was an employee of Analysis Group at the time of this analysis, which received research funding from Pfizer Inc., to conduct this study.

# Introduction, Methods, and Patients

## Introduction

- Many patients with AD cannot adequately control their disease with topical regimens alone and may require advanced treatment options, such as phototherapy and/or systemic agents<sup>1</sup>

## Objectives

- To describe treatment patterns for patients with AD who are initiating advanced therapy

## Methods

### Study Design

- Retrospective US claims database descriptive analysis
  - IQVIA Health Plan Claims Dataset<sup>a</sup> (Sep 29, 2016 to Jul 31, 2018)

### Outcomes

- Adherence/persistence rates
- Discontinuation rates at 6 months
- Subsequent therapy

### Patient Inclusion Criteria

- Aged  $\geq 12$  years with AD
- Newly initiated an advanced therapy after the availability of dupilumab (Mar 28, 2017)
  - Dupilumab
  - Oral corticosteroids
  - Phototherapy
  - Systemic immunosuppressant<sup>b</sup>
- $\geq 6$  months continuous enrollment before and after first advanced therapy claim

## Patient Characteristics at Index

	Total N=1980	Dupilumab N=265	Oral Corticosteroids N=1453	Systemic Immuno- suppressants N=99	Phototherapy N=163	P Value
Age, mean (SD), y	41.2 (17.4)	39.8 (14.9)	41.1 (17.3)	44.9 (18.7)	42.4 (20.2)	0.069
Female, n (%)	1209 (61.1)	136 (51.3)	911 (62.7)	62 (62.6)	100 (61.3)	0.007
TCS (preindex), n (%)	1290 (65.2)	186 (70.2)	962 (66.2)	69 (69.7)	73 (44.8)	<0.001

AD, atopic dermatitis; TCS, topical corticosteroid.


<sup>a</sup>Formerly known as IQVIA Real-World Data Adjudicated Claims Database. <sup>b</sup>Systemic immunosuppressants include methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil.

1. Sidbury R et al. *J Am Acad Dermatol.* 2014;71(2):327-349.


# Treatment Patterns

## Adherence

### Proportion of Days Covered at 6 Months




### Proportion of Adherent Patients<sup>a</sup> at 6 Months



## Persistence

### Persistence Rate<sup>b</sup>



### Discontinuation Rate<sup>c</sup> at 6 Months

Treatment	Discontinuation Rate (%)
Dupilumab	21.9%
Oral Corticosteroids	97.7%
Systemic Immunosuppressants	63.6%

PDC, proportion of days covered.

Phototherapy excluded from these analyses because it is not oral or injectable.

<sup>a</sup>Adherence defined as PDC ≥80%. <sup>b</sup>Time spent on therapy without a gap of >60 days, from Kaplan-Meier analysis. <sup>c</sup>Treatment gap >60 days, from Kaplan-Meier analysis.

# Subsequent Therapy and Conclusions



Copies of this poster obtained through this QR code are for your personal use only and may not be reproduced without permission from the authors. Scan to download a reprint of this poster. Copyright © 2020. All rights reserved.

## Subsequent Therapy During ≥6-Month Follow-Up

n (%)		Subsequent Therapy						
		Dupilumab	Oral corticosteroids	Cyclosporine	Mycophenolate mofetil	Azathioprine	Methotrexate	Phototherapy
Index Therapy	Dupilumab N=265	–	46 (17.4)	4 (1.5)	1 (0.4)	2 (0.8)	0 (0.0)	1 (0.4)
	Oral Corticosteroids N=1453	114 (7.8)	–	14 (1.0)	9 (0.6)	6 (0.4)	48 (3.3)	29 (2.0)
	Systemic Immunosuppressants N=99	18 (18.2)	23 (23.2)	–	–	–	–	3 (3.0)
	Phototherapy N=163	4 (2.5)	21 (12.9)	1 (0.6)	0 (0.0)	0 (0.0)	3 (1.8)	–

## Conclusions

- Challenges remain for patients with AD who require advanced therapy
- Oral corticosteroids are the most frequently used advanced therapy (73.4%)
- <70% of patients are adherent to their treatment regimen, and >20% discontinue within 6 months